Inventor
JACOBS JEFFREY W
US36 patents
⚠️ This page may combine multiple inventors who share the name “JACOBS JEFFREY W”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARDELYX INC
27 patentsUS10272079B2Apr 30, 2019
NHE3-binding compounds and methods for inhibiting phosphate transport
ARDELYX INC5 citations83
US9408840B2Aug 9, 2016
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
ARDELYX INC6 citations83
US8916569B2Dec 23, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8815908B2Aug 26, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8815910B2Aug 26, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8809339B2Aug 19, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC8 citations83
US11318129B2May 3, 2022
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC1 citations72
US10543207B2Jan 28, 2020
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations72
US10968246B2Apr 6, 2021
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC2 citations71
US10392413B2Aug 27, 2019
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC3 citations71
US10376481B2Aug 13, 2019
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations71
US10940146B2Mar 9, 2021
NHE3-binding compounds and methods for inhibiting phosphate transport
ARDELYX INC1 citations62
US9006281B2Apr 14, 2015
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC1 citations62
US8969377B2Mar 3, 2015
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations62
US12016856B2Jun 25, 2024
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC0 citations61
US11813304B2Nov 14, 2023
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations61
US9433640B2Sep 6, 2016
Compositions and methods for treating hyperkalemia
ARDELYX INC2 citations60
US9301951B2Apr 5, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9289429B2Mar 22, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9289430B2Mar 22, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9278102B2Mar 8, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US12084472B2Sep 10, 2024
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC0 citations50
US9919006B2Mar 20, 2018
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9867848B2Jan 16, 2018
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9655921B2May 23, 2017
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9549947B2Jan 24, 2017
Pharmaceutical compositions for treating hyperkalemia
ARDELYX INC0 citations49
US9545425B2Jan 17, 2017
Pharmaceutical compositions for treating hyperkalemia
ARDELYX INC0 citations49